TABLE 3.

Oligonucleotides used in this study

PrimerSequenceaDescription or restriction site(s)
13GTTGTAAAACGACGGCCAGTGpUC forward
17GGAAACAGCTATGACCATGpUC reverse
1CGCGGATCCAAGTATACTGCTATGAGCTACBamHI
2CAAGGAGCTCTTGTGCAGCGTGTAAGATATGAATCAAGTGATSacI/BsgI
4TCAGATCTCGAGTTGACCGTGACCGAAACXhoI
5CCGGGTACCTTGTGCAGTCGAAGTTAGAGTGCCCTATTCKpnI/BsgI
7AATCTCGAGTTGTGCAGTGCGGGTAACAATTCTCGGCGXhoI/BsgI
8CCCAAGCTTTTACTTCCTAGTTCTTGTCTCHindIII
11CGCGGATCCTGTCTATATTATCTCGGTAGATCBamHI
12CAAGGAGCTCTTGTGCAGTCAACTCATAGATCACAACATTAACACSacI/BsgI
57CGCGGATCCTCAATTGTGGGAAGTTATCTAATAAGCCBamHI
58CACTACTAGTTAAACACTTGTAGGAGSpeI
60CCCAAGCTTTTGAACCACGTAAAGTGCTGTHindIII
61CCGGGTACCTTGTGCAGCCTGTAAGGACTTCTAAACCKpnI/BsgI
2984GGTACCCGAGGGAGTTGCCTTCACTATGTGCGT TGAGKpnI/BcgI
2985CTCGAGCTGTTCTTGTTGATCTGTGTTTGGTXhoI
2986GGATTCTGACAGTGTTCCTTATTTTATCTAGBamHI
2987GAGCTCCGACCGCGGTGCATCTGTTACCAGGTTAGCCSacI/BcgI
2990GGTACCCGACTCCTGTGCCTTGTCGTACCAGAGAAACKpnI/BcgI
2991CTCGAGGAACAGGAATGGACACTAATATATAXhoI
2992GGATCCCCATTCTTTATTTTATTTTCTGCTABamHI
2993GAGCTCCGAGGCATCTGCTAATAATTTTCCGTTTCAASacI/BcgI
  • a Restriction sites are indicated in boldface.